Cowen and Company downgraded Raptor Pharmaceutical Corp. (NASDAQ:RPTP) to Market Perform in a statement released earlier today.
- Updated: September 16, 2016
Cowen and Company has downgraded Raptor Pharmaceutical Corp.(NASDAQ:RPTP) to Market Perform in a report released on Friday September 16 2016.
Showing a price of $8.98, Raptor Pharmaceutical Corp. (NASDAQ:RPTP) traded 0.11% higher on the day. The last stock close is up 61.46% relative to the two hundred day average, compared to the S&P 500 Index which has fallen -0.01% over the same period. Raptor Pharmaceutical Corp. has logged a 50-day average of $7.16 and 200-day average of $5.57. 3,023,527 shares of Raptor Pharmaceutical Corp. were exchanged, up from ann average volume of 1,802,600
See Chart Below:
Raptor Pharmaceutical Corp. has a one-year low of $2.94 and a one-year high of $8.99. The company’s market cap is currently $0.0.
A total of 6 analysts have reported on Raptor Pharmaceutical Corp.. Three analysts rate the company a strong buy, one firm rate the company a buy, four firms rate the stock a hold, 0 rate the stock to underperform, and lastly 0 brokeragesrate the stock as sell with a one year target price of $7.33
General Company Details For Raptor Pharmaceutical Corp. (NASDAQ:RPTP)
Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine (as mercaptamine bitartrate), is indicated as an orphan medicinal product for the management of nephropathic cystinosis. Its QUINSAIR is a formulation of the antibiotic drug levofloxacin, and suitable for inhalation via a nebulizer. It is engaged in developing MP-376 for non-CF bronchiectasis (BE) and nontuberculous mycobacteria (NTM) lung infections. It is also engaged in developing RP105 and RP106 for various diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.